Braveheart Bio Inc. is targeting up to $318.8 million in an initial public offering in the United States, according to the company.
The clinical-stage biopharmaceutical company is backed by venture capital firm a16z, according to the company.
Braveheart Bio targets up to $318.8M in US IPO
The clinical-stage biopharmaceutical firm backed by a16z aims to raise up to $318.8 million in its initial public offering, according to company filings.
Listen
Pavel Danilyuk
Sources
Spotted an error?
Report a correction.